IP Library › Granted Patent US 11,518,800
Granted Patent B2
US 11,518,800 · App. 16/074,166 · Granted Dec 6, 2022

Mutations that drive VH4 antibody autoreactivity

Inventor: Nancy Monson (Ovilla, TX)
Assignee: The Board of Regents of The University of Texas System
C07K16/18G01N33/583G01N33/6896C07K2317/565C07K2317/567
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,518,800
App. No.
16/074,166
Granted
Dec 6, 2022
Kind
B2
Abstract

Antibodies exhibiting a specific genetically modified signature associated with certain diseases of the central nervous system, like multiple sclerosis (MS) and clinically isolated syndrome have been identified. These antibodies recognize and bind with certain tissues in the brain and central nervous system and thus are useful as therapeutics, in the production of animal disease models, targets for therapies and as part of assays of the central nervous system.

Claims (14)

1. A recombinant antibody or antigen-binding fragment thereof, wherein the recombinant antibody or fragment comprises:

(a) heavy chain CDR1 comprising GGAVSNYY (SEQ ID NO: 65), heavy chain CDR2 comprising IYINGTT (SEQ ID NO: 66) and heavy chain CDR3 comprising ARWGALLGDYYYGLDV (SEQ ID NO: 67); and

light chain CDR1 comprising QSLLHSNEYIY (SEQ ID NO: 68), light chain CDR2 comprising LAS and light chain CDR3 comprising MQALEAPWT (SEQ ID NO: 69); or

(b) heavy chain CDR1 comprising GGSINNYY (SEQ ID NO: 70), heavy chain CDR2 comprising IYYNGNI (SEQ ID NO: 71) and heavy chain CDR3 comprising GIGYSAVAAGTVDY (SEQ ID NO: 72); and

light chain CDR1 comprising QGISSG (SEQ ID NO: 73), light chain CDR2 comprising DAS and light chain CDR3 comprising QQFNTFPYT (SEQ ID NO: 74).

2. The antibody or fragment of claim 1 , wherein said antibody or fragment has a heavy chain variable region comprising SEQ ID NO: 25 and a light chain variable region comprising SEQ ID NO: 47, or a heavy chain variable region comprising SEQ ID NO: 31 and a light chain variable region comprising SEQ ID NO: 35.

3. The recombinant antibody or fragment of claim 1 , wherein the recombinant antibody or fragment has mutations at both codon position 40 and codon position 81.

4. The recombinant antibody or fragment of claim 1 , wherein the recombinant antibody or fragment has a mutation at codon position 40.

5. The recombinant antibody or fragment of claim 1 , wherein the recombinant antibody or fragment has a mutation at codon position 81.

6. The recombinant antibody or fragment of claim 1 , wherein the recombinant antibody or fragment has a serine at codon position 40.

7. The recombinant antibody or fragment of claim 1 , wherein the recombinant antibody or fragment has an asparagine at codon position 81.

8. The antibody or fragment of claim 1 , wherein said recombinant antibody or fragment is linked to a toxin, a drug or a prodrug.

9. The antibody or fragment of claim 1 , wherein said recombinant antibody or fragment is linked to a label.

10. The antibody or fragment of claim 9 , wherein said label is a chromophore, fluorophore, chemilluminescent compound, dye, contrast agent, or radioabel.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2018
From: MONSON, NANCY
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 046818/0995 →
Continuity (2)
Provisional Application 62289736 · Feb 1, 2016
Related Publication 20210214423A1 · Jul 15, 2021